Glaxo Faces Another Antitrust Suit Over Relafen Patent

Law360, New York (October 1, 2004, 12:00 AM EDT) -- GlaxoSmithKline, which already has agreed to pay over $250 million to settle charges it broke antitrust law by trying to block generic competition for the arthritis drug Relafen, is facing accusations of antitrust violations and patent gaming in yet another complaint.

In May, the U.K. drug maker agreed to pay $75 million to settle a consumer class action lawsuit brought by advocacy groups that claimed Glaxo falsely obtained a patent for the drug by intentionally failing to disclose an earlier publication that identified the compound used...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.